Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

1. Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study

Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study Numerous pretreatment risk classification tools are available for prostate cancer. Which tool is best in predicting prostate cancer death is unclear.To systematically compare the prognostic performance of the most commonly used pretreatment risk stratification tools for prostate cancer.A nationwide cohort study was conducted, including 154 811 men (...) in Prostate Cancer data Base Sweden (PCBaSe) 4.0 diagnosed with nonmetastatic prostate cancer during 1998-2016 and followed through 2016.We compared the D'Amico, National Institute for Health and Care Excellence (NICE), European Association of Urology (EAU), Genito-Urinary Radiation Oncologists of Canada (GUROC), American Urological Association (AUA), National Comprehensive Cancer Network (NCCN), and Cambridge Prognostic Groups (CPG) risk group systems; the Cancer of the Prostate Risk Assessment (CAPRA

2019 EvidenceUpdates

2. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial

Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial Taxane-platinum combinations have shown promising activity in metastatic castration-resistant prostate cancers in single-group clinical studies but not in randomised trials. Distinct biological subsets of the disease might derive the greatest benefit from the addition of platinum. We aimed to determine whether adding carboplatin to cabazitaxel (...) would improve the outcomes of men with metastatic castration-resistant prostate cancer.We did a phase 1-2, open label, randomised study at two centres in men with progressive metastatic castration-resistant prostate cancer. In phase 1, patients received intravenous cabazitaxel 20-25 mg/m2 and intravenous carboplatin area under the curve (AUC) 3-4 mg/mL per min every 21 days. The maximum tolerated dose was defined as the highest dose cohort studied in which one of six or fewer patients experienced

2019 EvidenceUpdates

3. Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V

Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Apalutamide (Prostatakarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 29 April 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A19-09 Apalutamide (...) (prostate cancer) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-09 Version 1.0 Apalutamide (prostate cancer)) 24 April 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Apalutamide (prostate cancer) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 24 January 2019 Internal

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

4. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study

Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study In the phase 3 TITAN study, the addition of apalutamide to androgen deprivation therapy (ADT) significantly improved the primary endpoints of overall survival and radiographic progression-free survival in patients with metastatic castration-sensitive prostate cancer. We aimed to assess health-related quality of life (...) (HRQOL) in TITAN, including pain and fatigue.In this randomised, placebo-controlled, double-blind, phase 3 study, patients with metastatic castration-sensitive prostate cancer (defined as not receiving ADT at the time of metastatic disease progression) aged 18 years and older, receiving continuous ADT (selected at the investigator's discretion), and with an Eastern Cooperative Oncology Group performance status score of 0 or 1 were randomly assigned (1:1), using an interactive web response system

2019 EvidenceUpdates

5. Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis

Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis Indirect Comparisons of Efficacy Between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go (...) your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Review Eur Urol Actions 2019 Oct 31 [Online ahead of print] Indirect Comparisons of Efficacy Between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis

2019 EvidenceUpdates

6. Canadian Urological Association (CUA) -Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC)

Canadian Urological Association (CUA) -Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC) CUAJ • October 2019 • Volume 13, Issue 10 © 2019 Canadian Urological Association 307 Cite as: Can Urol Assoc J 2019;13(10):307-14. http://dx.doi.org/10.5489/cuaj.6136 Published online June 25, 2019 MEDLINE search of the English language and conference proceedings were used to produce the present document. Wherever Level 1 evidence is lacking (...) , the guideline attempts to provide expert opinion to aid in the management of patients. Levels of evidence and grades of recommendation employ the International Consultation on Urologic Disease (ICUD)/ WHO modified Oxford Center for Evidence-Based Medicine grading system. Based on a modified GRADE methodology, the strength of each recommendation is represented by the words STRONG or WEAK. Introduction Castration-resistant prostate cancer (CRPC) is defined by dis - ease progression despite castrate levels

2019 Canadian Urological Association

7. High Dose Rate Brachytherapy versus Low Dose Rate Brachytherapy for the Treatment of Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness

High Dose Rate Brachytherapy versus Low Dose Rate Brachytherapy for the Treatment of Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness High Dose Rate Brachytherapy versus Low Dose Rate Brachytherapy for the Treatment of Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need High Dose Rate Brachytherapy versus Low Dose Rate Brachytherapy for the Treatment of Prostate Cancer: A Review of Clinical Effectiveness (...) and Cost-Effectiveness High Dose Rate Brachytherapy versus Low Dose Rate Brachytherapy for the Treatment of Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Last updated: February 14, 2019 Project Number: RC1070-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of high-dose-rate versus low-dose-rate brachytherapy for the treatment of prostate cancer? What

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

8. Hydrogel Spacers for Patients with Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness

Hydrogel Spacers for Patients with Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Hydrogel Spacers for Patients with Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Hydrogel Spacers for Patients with Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Hydrogel Spacers for Patients with Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Last updated (...) : February 22, 2019 Project Number: RC1069-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of hydrogel spacers for patients with prostate cancer? What is the cost-effectiveness of hydrogel spacers for patients with prostate cancer? Key Message Three systematic reviews, one randomized controlled trial (described within two eligible reports), seven cohort studies, two economic evaluations

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

9. Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines

Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines | CADTH.ca Find the information you need Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines Last updated: August 22, 2019 Project Number: RA1060-000 Product Line: Research Type: Devices and Systems (...) Report Type: Reference List Result type: Report Question What is the clinical utility of prostate-specific antigen testing for prostate cancer? What are the evidence-based guidelines on the use of prostate-specific antigen testing for prostate cancer screening? Key Message Two systematic reviews were identified regarding the clinical utility of prostate-specific antigen testing for prostate cancer. In addition, five evidence-based guidelines were identified regarding the use of prostate-specific

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

10. Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines

Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines Last updated: September 5, 2019 Project Number (...) : RA1061-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What is the clinical effectiveness of radical prostatectomy for early-stage or screen-detected prostate cancer? What is the clinical effectiveness of radiation therapy for early-stage or screen-detected prostate cancer? What are the evidence-based guidelines on the use of radical prostatectomy for prostate cancer? What are the evidence-based guidelines on the use of radiation therapy

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

11. Androgen Receptor Targeted Agents for Castration Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness

Androgen Receptor Targeted Agents for Castration Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Androgen Receptor Targeted Agents for Castration Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Androgen Receptor Targeted Agents for Castration Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Androgen Receptor Targeted Agents for Castration (...) Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Last updated: June 6, 2019 Project Number: RC1127-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of varying treatment sequences of androgen receptor targeted agents in patients with castrate-resistant prostate cancer? What is the comparative cost-effectiveness of varying treatment sequences of androgen

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

12. Abiraterone (Zytiga) for Prostate Cancer Resubmission - Details

Abiraterone (Zytiga) for Prostate Cancer Resubmission - Details Abiraterone (Zytiga) for Prostate Cancer Resubmission - Details | CADTH.ca Find the information you need Abiraterone (Zytiga) for Prostate Cancer Resubmission - Details Abiraterone (Zytiga) for Prostate Cancer Resubmission - Details Project Number pCODR 10201 Brand Name Zytiga (Resubmission) Generic Name Abiraterone Strength 250 mg & 500 mg Tumour Type Genitourinary Indication Prostate Cancer Funding Request Newly diagnosed high (...) -risk metastatic castration sensitive prostate cancer without small-cell histologic features. Patients required to have at least two of the three following high-risk factors: Gleason score of 8 or more, at least 3 bone lesions, and presence of visceral metastasis. Less than 3 months of androgen deprivation therapy (or orchiectomy) for metastatic disease. Eligible for abiraterone therapy. Review Status Under Review Pre Noc Submission No NOC Date February 15, 2018 Manufacturer Janssen Inc. Sponsor BC

2019 CADTH - Pan Canadian Oncology Drug Review

13. Xtandi for non-metastatic Castration-Resistant Prostate Cancer – Details

Xtandi for non-metastatic Castration-Resistant Prostate Cancer – Details Xtandi for non-metastatic Castration-Resistant Prostate Cancer – Details | CADTH.ca Find the information you need Xtandi for non-metastatic Castration-Resistant Prostate Cancer – Details Xtandi for non-metastatic Castration-Resistant Prostate Cancer – Details Project Number pCODR 10149 Brand Name Xtandi Generic Name Enzalutamide Strength 40 mg Tumour Type Genitourinary Indication Non-metastatic castration-resistant (...) prostate cancer Funding Request High risk, non-metastatic castration-resistant prostate cancer Review Status Notification to Implement Issued Pre Noc Submission Yes NOC Date December 20, 2018 Manufacturer Astellas Pharma Canada, Inc. Sponsor Astellas Pharma Canada, Inc. Submission Date September 24, 2018 Submission Deemed Complete October 9, 2018 Submission Type New Indication Prioritization Requested Stakeholder Input Deadline ‡ October 9, 2018 Check-point meeting November 20, 2018 pERC Meeting

2019 CADTH - Pan Canadian Oncology Drug Review

14. Zytiga for Prostate Cancer – Details

Zytiga for Prostate Cancer – Details Zytiga for Prostate Cancer – Details | CADTH.ca Find the information you need Zytiga for Prostate Cancer – Details Zytiga for Prostate Cancer – Details Project Number pCODR 10166 Brand Name Zytiga Generic Name Abiraterone Strength 250 mg & 500 mg Tumour Type Genitourinary Indication Prostate Cancer Funding Request Newly diagnosed with metastatic prostate cancer without small-cell histologic features (may have received prior surgery or radiation therapy (...) for local disease or palliative therapy); Less than 3 months of androgen deprivation therapy for metastatic disease (may have received prior adjuvant/neoadjuvant hormone therapy); Eligible for abiraterone therapy Review Status Withdrawn Clarification BC Cancer Agency has requested a voluntary withdrawal of the pCODR 10166 Abiraterone (Zytiga) for PC Submission. As per pCODR Procedures B3.1.6.2 b), the pCODR Provincial Advisory Group has agreed to the request to withdraw and decided to not continue

2019 CADTH - Pan Canadian Oncology Drug Review

15. Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines

Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines Last updated: October 3, 2019 Project Number: RA1062-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What (...) is the clinical effectiveness of cryotherapy for early-stage or screen-detected prostate cancer? What are the evidence-based guidelines on the use of cryotherapy for prostate cancer? Key Message Four systematic reviews (including one systematic review with meta-analysis) were identified regarding the clinical effectiveness of cryotherapy for early-stage or screen-detected prostate cancer. In addition, five evidence-based guidelines were identified regarding the use of cryotherapy for prostate cancer. Files

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

16. Darolutamide (TBD) for Non-Metastatic Castration Resistant Prostate Cancer – Details

Darolutamide (TBD) for Non-Metastatic Castration Resistant Prostate Cancer – Details Darolutamide (TBD) for Non-Metastatic Castration Resistant Prostate Cancer – Details | CADTH.ca Find the information you need Darolutamide (TBD) for Non-Metastatic Castration Resistant Prostate Cancer – Details Darolutamide (TBD) for Non-Metastatic Castration Resistant Prostate Cancer – Details Project Number pCODR 10196 Brand Name TBD Generic Name Darolutamide Tumour Type Genitourinary Indication Non (...) -Metastatic Castration Resistant Prostate Cancer Funding Request In combination with androgen depravation therapy (ADT), for the treatment of patients with non-metastatic castration resistant prostate cancer who are at high risk of developing metastases (high risk defined as prostate-specific antigen doubling time ≤ 10 months) during continuous ADT, and have a good Eastern Cooperative Oncology Group (ECOG) performance status Review Status Under Review Pre Noc Submission Yes NOC Date Manufacturer Bayer Inc

2019 CADTH - Pan Canadian Oncology Drug Review

17. Apalutamide (Erleada) for Metastatic Castration-Sensitive Prostate Cancer - Details

Apalutamide (Erleada) for Metastatic Castration-Sensitive Prostate Cancer - Details Apalutamide (Erleada) for Metastatic Castration-Sensitive Prostate Cancer - Details | CADTH.ca Find the information you need Apalutamide (Erleada) for Metastatic Castration-Sensitive Prostate Cancer - Details Apalutamide (Erleada) for Metastatic Castration-Sensitive Prostate Cancer - Details Project Number pCODR 10200 Brand Name Erleada Generic Name Apalutamide Tumour Type Genitourinary Indication Metastatic (...) Castration-Sensitive Prostate Cancer Funding Request For the treatment of metastatic castration-sensitive prostate cancer (mCSPC) Review Status Pending Pre Noc Submission Yes NOC Date Manufacturer Janssen Inc. Sponsor Janssen Inc. Submission Date (Target Date) October 15, 2019 Submission Type New Indication Prioritization Requested Stakeholder Input Deadline (target date based on target submission date) ‡ October 29, 2019 Check-point meeting (target date) pERC Meeting (target date) Initial Recommendation

2019 CADTH - Pan Canadian Oncology Drug Review

18. Interstitial low-dose-rate brachytherapy for localized prostate cancer - rapid report

Interstitial low-dose-rate brachytherapy for localized prostate cancer - rapid report 1 Translation of the key statement of the rapid report N17-04 Interstitielle Low-Dose-Rate-Brachytherapie beim lokal begrenzten Prostatakarzinom (Version 1.0; Status: 19 October 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding (...) . Extract IQWiG Reports – Commission No. N17-04 Interstitial low-dose-rate brachytherapy for localized prostate cancer 1 Extract of rapid report N17-04 Version 1.0 Brachytherapy for prostate cancer 19 October 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Interstitial low-dose-rate brachytherapy for localized prostate cancer Commissioning agency: Federal Joint Committee Commission awarded

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

19. Enzalutamide (Xtandi) - castration-resistant prostate cancer (CRPC)

Enzalutamide (Xtandi) - castration-resistant prostate cancer (CRPC) 1 Published 07 October 2019 1 SMC2195 enzalutamide 40mg soft capsules (Xtandi®) Astellas Pharma Ltd 06 September 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission considered under the orphan equivalent process (...) enzalutamide (Xtandi ® ) is not recommended for use within NHSScotland. Indication under review: The treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC). In a phase III study in men with high-risk non-metastatic CRPC enzalutamide was superior to placebo for metastasis-free survival. High-risk was defined as prostate specific antigen (PSA) doubling time =10 months and PSA =2 nanograms/mL. Both groups received on-going androgen-deprivation therapy or had undergone

2019 Scottish Medicines Consortium

20. The Effects of a Plant-Based Diet and Stress Reduction Techniques on PSA Doubling Time in Prostate Cancer Recurrence

The Effects of a Plant-Based Diet and Stress Reduction Techniques on PSA Doubling Time in Prostate Cancer Recurrence "The Effects of a Plant-Based Diet and Stress Reduction Techniques on P" by Amanda Barclay and Jacob McAvoy < > > > > > Title Author Date of Graduation Summer 8-10-2019 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Prostate cancer is the most common cancer affecting men. It is also very common for men (...) to suffer from recurrence after primary therapy is completed. The current most commonly used therapies for prostate cancer recurrence, hormonal therapy and radiation, have significant side effects. It is known that diet influences cancer prevention, progression, and recurrence. A plant-based diet, especially when combined with stress reduction techniques, may be a useful therapeutic option with fewer side effects for men with recurrent prostate cancer. This review examines the effects of a plant-based

2019 Pacific University EBM Capstone Project